Chlorothiazide pharma grade API, identified in compendial literature as 6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, CAS 58-94-6, molecular formula C7H6ClN3O4S2, and molecular weight 295.72 g/mol, is released for formulation into tablet, capsule, granule, injection, and oral or injectable dosage forms. The material is supplied as the free sulfonamide acid and as the sodium salt; the free acid is intended for oral solid intermediates, while the sodium salt is specified for aqueous injectable processing. Both forms are produced under ICH Q7 GMP and are controlled against current compendial monographs, including the USP, Ph.Eur., and JP chlorothiazide monographs. No single industry-wide model code exists for chlorothiazide API; manufacturers assign internal grade designations linked to particle-size reduction and sterility-endotoxin control levels, and the compendial monograph identity remains the principal product model.

The pharmacologic action of chlorothiazide is inhibition of sodium-chloride reabsorption in the distal convoluted tubule. This mechanism is not a formulation property, but it generates patient-dose strengths that influence API particle-size and impurity specifications. Oral tablets and capsules typically process chlorothiazide at dose strengths of 250 mg and 500 mg; injectable chlorothiazide sodium is presented as a sterile powder for intravenous administration after reconstitution. The API must therefore be distinguished from non-pharmaceutical grades by its control of related substances, residual solvents, elemental impurities, and, for injectable use, bacterial endotoxins and particulate matter.

What Release Specifications Govern Assay, Related Substances, and Residual Solvents?

Release testing for chlorothiazide pharma grade API includes identification, assay, chromatographic purity, loss on drying, residue on ignition, residual solvents, elemental impurities, and route-specific tests. Identification is performed against a reference standard by infrared absorption spectrophotometry and HPLC retention time. Assay is performed by stability-indicating HPLC with UV detection and is normally controlled at 98.0–102.0% on the dried basis; the exact acceptance criterion is defined by the relevant pharmacopoeial monograph and marketing authorization.

Related substances are controlled by HPLC with area normalization and comparison to reference standard. For a maximum daily dose not exceeding 2 g/day, ICH Q3A sets reporting, identification, and qualification thresholds of 0.05%, 0.10%, and 0.15%, respectively; these thresholds are applied unless a stricter monograph limit is specified. Residual solvents are tested by headspace gas chromatography per USP <467> or Ph.Eur. 2.4.24 using ICH Q3C Option 1. Elemental impurities are controlled under ICH Q3D and analyzed by USP <232>/<233>. The API is not released as sterile unless specified; nonsterile solid oral grades require microbial enumeration per USP <61> and USP <62>.

The stability-indicating HPLC method must separate chlorothiazide from its principal synthesis-related impurities and from photodegradation products. Forced degradation studies under ICH Q1B typically expose the drug substance to acid, base, oxidative, thermal, and photolytic stress; the resulting degradant profile is used to establish peak purity. Sulfonamide-containing thiazides may be sensitive to alkaline hydrolysis and oxidizing conditions, and the method must show baseline resolution of the known impurity markers. This is critical because the free acid and sodium salt may exhibit different degradation kinetics in solution; the injectable product therefore requires solution-state stability studies during aseptic processing.

Micronized chlorothiazide for direct compression is controlled by laser diffraction particle-size analysis using USP <429> / ISO 13320-1:2020. The route-specific specification for oral solid grade may set D10, D50, and D90 limits derived from dissolution and content uniformity requirements, not from a pharmacopoeial numeric limit. Published data for a universal chlorothiazide particle-size specification are limited; manufacturer filing data define the applicable distribution. For low-solubility thiazide APIs processed in direct compression, a D90 below 50 µm is a common target to support dissolution, but over-micronization can increase electrostatic adhesion and reduce flow. The resulting cohesive powder may require glidant addition and force feeder control on rotary tablet presses.

Bulk and tapped density are measured by USP <616> Methods I and II. Direct-compression blends of chlorothiazide may exhibit low bulk density and require precompression or feed-frame agitation. On production rotary presses, die fill variation is controlled by maintaining a constant hopper level and by setting turret speed to avoid incomplete filling. For capsule filling, filled capsule weight variation is minimized by controlling powder bed height and adjusting tamping pins. These process controls are not uniform across all container sizes; they must be re-established after particle-size specification changes.

When relative humidity exceeds 60%, moisture uptake is limited but not negligible for some milled lots; blend handling should minimize open storage times, and finished granules should be dried to a loss-on-drying consistent with the formulation. Chlorothiazide should not be dry-blended with strong oxidizing agents or amine-based additives that can destabilize the sulfonamide moiety unless compatibility data support the combination. Compatibility with common tablet fillers and disintegrants must be confirmed by formulation development studies under ICH Q1A; no inference of compatibility should be made from API stability alone.

When the API Is Destined for Injectable Manufacture, Sterility Assurance and Endotoxin Control Become Release-Critical

Injectable chlorothiazide sodium is manufactured to a different control level than oral-grade free acid. The sodium salt is dissolved in Water for Injection, filtered through a sterilizing-grade membrane, and then lyophilized or filled as a sterile powder; the API may also be supplied as a low-endotoxin nonsterile powder for terminal sterilization after filling. Process viability depends on the selected sterilization method and on the bioburden of the incoming API. Bioburden is controlled by USP <61> and USP <62>, and bacterial endotoxins are tested by USP <85> / Ph.Eur. 2.6.14. The acceptance limit for bacterial endotoxins is derived from the maximum intravenous dose, not fixed at the API level; for a 70 kg patient, K = 5 EU/kg, and a maximum intravenous dose of 1 g/day, the calculated limit is 0.35 EU/mg. Regional pharmacopoeial K/M calculation controls the final value.

Particulate matter in the finished injection must comply with USP <788> / Ph.Eur. 2.9.19. For small-volume parenterals, the subvisible limits are 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm; large-volume limits are calculated per milliliter. The API itself is not typically subjected to finished-product particulate limits, but the manufacturer must control insoluble foreign matter and ensure that solution clarity after reconstitution meets the marketing authorization. Sterility of sterile API is tested by membrane filtration per USP <71> / Ph.Eur. 2.6.1. Container closure integrity for lyophilized powder is evaluated using USP <1207>; the selection of rubber stoppers and seals must be qualified for moisture ingress and vacuum retention.

Bioburden sampling of injectable chlorothiazide sodium is performed using membrane filtration of a solution prepared in sterile phosphate buffer or Water for Injection. The pre-filtration bioburden limit is based on the capacity of the sterilizing-grade filter to retain a minimum of 10⁷ CFU/cm² of Brevundimonas diminuta per ASTM F838-20 or equivalent filter validation. Actual production batches should operate well below this validated retention threshold to maintain a sterility assurance level of 10⁻⁶. This is a process boundary that requires coordination between API manufacturer, sterile manufacturer, and filter membrane supplier.

For injectable processing, residual water in lyophilized powder is controlled by Karl Fischer titration per USP <921> Method Ia, with typical release limits below 2.0% for the sterile powder. Residual solvents are especially critical for the injectable grade because solvents such as acetone or methanol must be reduced to ICH Q3C limits before sterile filtration. Published data for lyophilized chlorothiazide sodium specific residual moisture limits are limited; the manufacturer’s product dossier defines the exact specification. The reconstituted solution is generally alkaline and pH-adjusted; pH limits are product-specific and are established during injectable formulation development.

Wet granulation is often applied to chlorothiazide tablet and capsule intermediates when direct compression blend flow is inadequate. Granulating fluid may be purified water or a low-viscosity binder solution. In high-shear mixers, granulation endpoint is determined by impeller power consumption, impeller torque, or near-infrared moisture monitoring rather than by fixed time alone. After fluid-bed drying, granule moisture is typically controlled at 1.0–2.0% loss on drying for tablet compression; the exact target depends on the filler-binder system and the tablet press force feeder configuration. Over-granulation produces dense granules that may reduce API dissolution, while under-granulation produces friable granules that segregate during handling. Dry granulation by slugging or roller compaction is also feasible, but the poor flow of the unmilled API often requires a forced feed device on the roller compactor.

Capsule filling operations with chlorothiazide granules require control of granule particle size above 0.5 mm to avoid excessive fines on tamping pins. Bulk density of the granulation should be matched to the target capsule fill volume. For low-dose capsule formulations, API content uniformity is improved by geometric dilution before final blending, and blend uniformity testing is performed per USP <905> or the equivalent Ph.Eur. content uniformity monograph. Granule size distribution after sieving is monitored because irregular granules can create segregation during transfer to the capsule machine hopper.

Route-Specific Salt Selection, Particle Size, and Comparative Differences Across Thiazide APIs

The product differs from technical-grade chlorothiazide and from other thiazide diuretics in several specification dimensions. Technical-grade material may contain uncontrolled heavy metals, residual solvents, and synthesis-related impurities that are not acceptable for pharmaceutical use. Pharma grade chlorothiazide is released with a complete certificate of analysis, current GMP documentation, and compendial method validation. It is not interchangeable with hydrochlorothiazide or chlorthalidone without dose adjustment because potency and pharmacokinetic profiles differ. The solid oral route normally uses the free acid, while the injectable route uses chlorothiazide sodium; this salt-form difference changes pH, solubility, and excipient compatibility in the preparation of the dosage form.

Compared with hydrochlorothiazide, chlorothiazide has a shorter duration of diuretic action and lower milligram potency; published dose equivalence is product-dependent and should not be used to switch formulations without clinical evaluation. The free acid is practically insoluble in water, which limits direct aqueous dissolution; the sodium salt is freely soluble in water and can be processed into injectable solutions. This distinction changes the analytical control strategy: injectable grade requires endotoxin, sterility, and particulate matter testing, while oral grade requires solid-state particle-size and flowability data.

Packaging for nonsterile chlorothiazide API consists of a low-density polyethylene inner liner inside a high-density polyethylene outer drum. For injectable grade, the powder may be filled into sterile Type I borosilicate vials with rubber stoppers and aluminum seals, or supplied in a double-bagged format for terminal sterilization under validated load configurations. Storage is controlled at 15–30°C; protect from light and moisture. Stability protocols follow ICH Q1A(R2) with long-term testing at 25°C/60% RH and accelerated testing at 40°C/75% RH for climatic zones I and II. Some manufacturers include 30°C/65% RH intermediates for zone IVb. Retest dates are assigned from the API stability program and are not equivalent to finished-product expiry dates.

In practice, the critical processing boundary for oral grade is the particle-size distribution after milling; lot-to-lot variation in particle size can shift tablet hardness, content uniformity, and dissolution. For injectable grade, the critical processing boundary is the bioburden and endotoxin profile entering the sterile filtration step. Both boundaries must be controlled through supplier change notification and annual product review under FDA 21 CFR 211.84 and ICH Q10. The product is therefore specified not as a single material but as a route-specific control package in which particle size, salt form, residual moisture, and microbial-endotoxin attributes are aligned to the intended dosage form.